Stock Taper 
ARTV
$11.09
▼ DOWN 7.12% (-0.85)
KEY STATISTICS
Market Cap$542.19 M
52w High$14.53
52w Low$2.22
Dividend Yield—
Frequency—
P/E-3.36
Volume222.79K
Shares Out.48.89M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Fred Aslan
ABOUT
SECTOR
Healthcare
WENT PUBLIC
July 19, 2024
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
115
PRICE TARGET
Target High$40.00
Target Low$35.00
Target Median$37.50
Target Consensus$37.50
UPCOMING EARNINGS
DateNov 11, 2026
DayWednesday
Rev. Est.—
NOV
11
WED
PRICE
$11.09 ▼ DOWN 7.12% (−$0.85)About Artiva Biotherapeutics, Inc.
https://www.artivabio.com ↗Artiva Biotherapeutics develops off-the-shelf NK cell therapies, including AB-101, for autoimmune diseases and cancers, with additional CAR-NK candidates, aiming to treat conditions like lupus, rheumatoid arthritis, and lymphoma.
INDUSTRY
Biotechnology
A PRODUCT ARTIVA BIOTHERAPEUTICS, INC. IS KNOWN FOR
AlloNK® (AB-101)
AlloNK® is an off-the-shelf NK cell therapy by Artiva, in clinical trials for autoimmune diseases and cancers like lupus nephritis and B-cell lymphomas, designed to be combined with monoclonal antibodies.
ETFS HOLDING THIS STOCK
ETFS HOLDING
46
LISTED HERE
9
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
36.26%
HOLDERS
56
TOP 12 OF 56 · RANKED BY POSITION SIZE
Ra Capital Management, L.P.
5am Venture Management, LLC
Vr Adviser, LLC
Venbio Partners LLC
Citadel Advisors LLC
Franklin Resources Inc
Revelation Capital Management, LLC
Blackrock, Inc.
Millennium Management LLC
Vanguard Group Inc
Wellington Management Group Llp
Propel Bio Management, LLC
RATINGS SNAPSHOT
Overall rating: B-
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score2
INSIDER TRADES
★
OFFICER: CHIEF MEDICAL OFFICER
Banerjee Subhashis
Purchase · 429 shares
2026-08-18
★
OFFICER: CHIEF MEDICAL OFFICER
Banerjee Subhashis
Sale · 429 shares
2026-08-18
★
DIRECTOR, 10 PERCENT OWNER:
RA CAPITAL MANAGEMENT, L.P.
Purchase · 24.9K shares
2026-07-31
★
DIRECTOR, 10 PERCENT OWNER:
RA CAPITAL MANAGEMENT, L.P.
Purchase · 20.8K shares
2026-07-29
MOST RECENT ANALYST GRADES
GRADE SUMMARY
BUY 2
OVERWEIGHT 1
OUTPERFORM 1
4 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 STTK | $7.04 | COMPARE |
 IFRX | $2.23 | COMPARE |
 ZNTL | $3.80 | COMPARE |
 ALXO | $2.00 | COMPARE |
 STRO | $20.45 | COMPARE |
 CNTB | $2.23 | COMPARE |
 GUTS | $0.66 | COMPARE |
 DTIL | $7.78 | COMPARE |